Literature DB >> 8392560

The entire vasoactive intestinal polypeptide molecule is required for the activation of the vasoactive intestinal polypeptide receptor: functional and binding studies on opossum internal anal sphincter smooth muscle.

S Chakder1, S Rattan.   

Abstract

UNLABELLED: Because no significant information exists regarding the structure-activity of vasoactive intestinal polypeptide (VIP) to gut smooth muscle, we performed functional studies in vitro on opossum internal anal sphincter (IAS) smooth muscle strips and supplemented them with binding studies to assess the ability of VIP, its fragments and analogs to inhibit [125I]VIP binding to IAS smooth muscle membranes. Binding of radiolabeled VIP to its receptor was specific, saturable and time- and temperature-dependent. Of all the substances tested, VIP was the most potent in causing a fall in the resting tension of the IAS and inhibiting [125I]VIP binding. VIP 2-28, VIP 10-28 and the putative VIP antagonists (1 x 10(-6) M) [4Cl-D-Phe6,Leu17]VIP (VIP analog) and (N-Ac-Tyr1, D-Phe2)-growth hormone-releasing factor [GRF] (1-29)-NH2 (GRF analog) caused significant inhibition of [125I]VIP binding, but had only minimal effect on the resting tension of the IAS. VIP 9-18 and VIP 1-12 had neither any significant effect nor inhibition of receptor binding. The rank order of potencies for inhibition of binding was VIP > VIP analog > VIP 10-28 = VIP 2-28 > GRF analog > peptide histidine isoleucine > VIP 9-18. The IC50 values for VIP, VIP analog, VIP 10-28, VIP 2-28, GRF analog and peptide histidine isoleucine were 9.6 x 10(-9), 1.6 x 10(-7), 5.5 x 10(-7), 6.2 x 10(-7), 1.2 x 10(-6) and 1.2 x 10(-5) M, respectively.
CONCLUSION: the full action of VIP is critically dependent upon the integrity of the entire VIP molecule.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8392560

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  VPAC1 receptors for imaging breast cancer: a feasibility study.

Authors:  Mathew L Thakur; Kaijun Zhang; Adam Berger; Barbara Cavanaugh; Sung Kim; Chaitra Channappa; Andrea J Frangos; Eric Wickstrom; Charles M Intenzo
Journal:  J Nucl Med       Date:  2013-05-07       Impact factor: 10.057

2.  Development of a voided urine assay for detecting prostate cancer non-invasively: a pilot study.

Authors:  Edouard J Trabulsi; Sushil K Tripathi; Leonard Gomella; Charalambos Solomides; Eric Wickstrom; Mathew L Thakur
Journal:  BJU Int       Date:  2017-02-16       Impact factor: 5.588

3.  Evidence for a role for vasoactive intestinal peptide in active vasodilatation in the cutaneous vasculature of humans.

Authors:  Lee Ann T Bennett; John M Johnson; Dan P Stephens; Adham R Saad; Dean L Kellogg
Journal:  J Physiol       Date:  2003-07-07       Impact factor: 5.182

4.  PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog.

Authors:  Mathew L Thakur; Mohan R Aruva; Jean Gariepy; Paul Acton; Satish Rattan; Shyam Prasad; Eric Wickstrom; Abass Alavi
Journal:  J Nucl Med       Date:  2004-08       Impact factor: 10.057

5.  PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer.

Authors:  Kaijun Zhang; Mohan R Aruva; Nylla Shanthly; Christopher A Cardi; Satish Rattan; Chirag Patel; Christopher Kim; Peter A McCue; Eric Wickstrom; Mathew L Thakur
Journal:  J Nucl Med       Date:  2007-12-12       Impact factor: 10.057

6.  Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation.

Authors:  Kaijun Zhang; Mohan R Aruva; Nylla Shanthly; Christopher A Cardi; Chirag A Patel; Satish Rattan; Gregory Cesarone; Eric Wickstrom; Mathew L Thakur
Journal:  Regul Pept       Date:  2007-07-06

7.  Agnathan VIP, PACAP and their receptors: ancestral origins of today's highly diversified forms.

Authors:  Stephanie Y L Ng; Billy K C Chow; Jun Kasamatsu; Masanori Kasahara; Leo T O Lee
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.